Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringCaitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Nature Communications|September 27, 2022
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphomaTatiana Erazo, Chiara M Evans, Daniel Zakheim, et al.
Transplantation and Cellular Therapy|August 9, 2022
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell LymphomaKarthik Nath, Ana Alarcon Tomas, Jessica Flynn, et al.
Blood|February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphomaClaire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Pageof 3